Gunnar Frostfeldt

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.

Lars Wallentin, Eva Swahn, Frederic Kontny et al. · PubMed · 1999 · 338 citations

N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease

Tomas Jernberg, Bertil Lindahl, Agneta Siegbahn et al. · Journal of the American College of Cardiology · 2003 · 131 citations

Inflammation, Neuropeptides, Cardiovascular Disease +9

The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: The FRISC II invasive troponin T electrocardiogram substudy

Erik Diderholm, Bertil Andrén, Gunnar Frostfeldt et al. · American Heart Journal · 2002 · 129 citations

Cardiovascular Disease, St Depression, Therapeutic Implications +6

Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II)

Gunnar Frostfeldt, Greger Ahlberg, G Gustafsson et al. · Journal of the American College of Cardiology · 1999 · 99 citations

Thrombosis, Biochemical Markers, Cardiovascular Disease +10

ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease

Erik Diderholm, Bertil Andrén, Gunnar Frostfeldt · ACC Current Journal Review · 2002 · 64 citations

Large Benefits, Percutaneous Coronary Intervention, Cardiovascular Disease +9